Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.52% on January 19, 2025, underperforming the CSI 300 index by 0.57 percentage points, ranking 28th among 31 sub-industries [4]. - Notable performers within the pharmaceutical sub-industries included offline pharmacies (+2.39%) and blood products (+0.11%), while sectors such as medical R&D outsourcing (-1.77%) and vaccines (-1.10%) lagged behind [4]. - Takeda's new drug Oveporexton has received acceptance for its market application in China, targeting narcolepsy type 1 (NT1) and showing promising results in clinical trials [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]

Core Viewpoint - Tianyi Medical has received a medical device registration certificate from the National Medical Products Administration for its product, a disposable continuous renal replacement therapy circuit, valid until January 13, 2031 [2]. Group 1 - The product name is "disposable continuous renal replacement therapy circuit" [2]. - The registration certificate number is 20263100049 [2]. - The effective period of the registration certificate is until January 13, 2031 [2].

Company News - Vanke A and Changsha Vanke Enterprise Co., Ltd. have added a new execution information of over 1.08 billion yuan [1] - Longi Green Energy has released a 2025 performance forecast, expecting a net loss of 6-6.5 billion yuan, while successfully scaling up the production of BC Generation II products and officially entering the energy storage sector [1] - Wanhua Chemical established Wanhua Chemical Group (Laizhou) New Energy Materials Technology Co., Ltd. with a registered capital of 740 million yuan on January 16 [1] - Zhiyuan Robotics has signed a memorandum of cooperation with Lens Technology, Thailand's SKY, and Com7 to establish a joint venture in Thailand to explore the implementation path of embodied intelligence industry [1] - Tianrongxin has stated that the company has technical reserves and layout in the commercial aerospace security field and will continue to expand research and application of new technologies and scenarios [1] - Sunlord Electronics claims its products are widely used in AI glasses, covering inductors, LTCC, antennas, and have been supplying major clients in related fields [1] - Tianyi Medical has recently received a medical device registration certificate for disposable continuous renal replacement therapy tubing from the National Medical Products Administration [1] Industry News - The National Bureau of Statistics has released the 2025 national economic data, with GDP exceeding 140 trillion yuan, a year-on-year growth of 5%, and the manufacturing sector expected to maintain its position as the world's largest for 16 consecutive years, driven by "Artificial Intelligence+" with storage chips and server production increasing by 22.8% and 12.6% respectively [1] - The Ministry of Industry and Information Technology, the National Development and Reform Commission, and four other departments have jointly issued opinions to cultivate and build a number of zero-carbon factories in the automotive, lithium battery, and photovoltaic industries by 2027 [1] - Hainan Free Trade Port has shown initial results in its first month of closure, with 5,132 new foreign trade registered enterprises, and border inspection agencies reporting a year-on-year increase of 31% and 27% in inspected personnel and transportation vehicles respectively [1] - The first day of the 2026 Spring Festival travel season (February 2) train tickets will go on sale on January 19, with the railway department introducing new services such as limited-time free refunds for mistakenly purchased tickets, expecting a significant increase in short- and medium-distance passenger flow [1]

Group 1 - Tianyi Medical has received a medical device registration certificate from the National Medical Products Administration for a disposable continuous renal replacement therapy circuit, which is a complete and integrated extracorporeal circulation system designed to meet clinical operational and safety needs in intensive care settings, compatible with the Nikkiso Aquarius blood purification device [1] Group 2 - Jinchong Co., Ltd. has announced that January 19 is the last conversion day for "Jinchong Convertible Bonds," and investors holding these bonds can convert them before market close on that day; after this date, unconverted bonds will be forcibly redeemed at a price of 100.2 yuan per bond, potentially leading to losses for investors [2] Group 3 - Beixin Building Materials has completed the payment of the principal and interest for the second phase of its ultra-short-term financing bonds for the year 2025, totaling 1.007 billion yuan, which has been transferred to the designated accounts of bondholders by the China Interbank Market Clearing House [3]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its product, a disposable continuous renal replacement therapy circuit [1] Group 1: Product Details - The registered product is a complete and integrated system designed for extracorporeal circulation, specifically for continuous renal replacement therapy [1] - The multi-channel design and comprehensive safety accessories of the product are tailored to meet the clinical operational and safety needs in intensive care environments [1] - The product is compatible with the Nikkiso Aquarius blood purification device [1] Group 2: Market Implications - The issuance of the registration certificate signifies the successful extension of the company's product registration, demonstrating ongoing compliance with regulatory requirements [1] - This development is expected to positively impact the company's market competitiveness and expansion [1]

Core Viewpoint - Tianyi Medical has received a medical device registration certificate from the National Medical Products Administration for a single-use continuous renal replacement therapy circuit, indicating a significant advancement in its product offerings in the renal therapy market [1] Group 1: Product Details - The newly certified product is designed to be used with the AQUARIUS series of continuous blood purification devices and specialized filters for continuous renal replacement therapy [1] - It supports various treatment modalities including slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), continuous venovenous hemodialysis with filtration (CVVHDF), therapeutic plasma exchange (TPE), and blood perfusion (HP) [1] - The product is responsible for the function of blood and fluid pathways, enhancing the efficiency and effectiveness of renal replacement therapies [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its disposable continuous renal replacement therapy circuit, indicating compliance with regulatory requirements and enhancing market competitiveness [1] Group 1: Product Details - The registered product is a complete, integrated, and reliable extracorporeal circulation circuit system designed for continuous renal replacement therapy in critical care settings [1] - The system features a highly integrated multi-tube design and comprehensive safety accessories to meet clinical operational and safety needs [1] - It is compatible with the Nikkiso Aquarius blood purification device, indicating its applicability in advanced medical settings [1] Group 2: Market Implications - The issuance of the registration certificate signifies a successful extension of the company's product registration, reinforcing its commitment to regulatory compliance [1] - This development is expected to positively impact the company's market competitiveness and ability to expand its market presence [1]

Group 1 - Kangfang Biotech's PD-1/CTLA-4 bispecific antibody KAITENI® has received approval for a new indication in the treatment of cervical cancer, marking the third indication for this drug [1] - Tianyi Medical has obtained product registration certificates for single-use continuous renal replacement therapy tubing and single-use hemodialysis tubing, both sterilized with ethylene oxide [2] - Jincheng Pharmaceutical's posaconazole enteric-coated tablets and injectable cefoperazone sodium have been approved, enhancing the company's competitiveness in the antifungal and anti-infection sectors [3] Group 2 - Prolo Pharma has received approval for the raw material drug succinate desvenlafaxine, expanding its product pipeline in the antidepressant treatment field [4] - Wantai Biological Pharmacy's first domestically produced nine-valent HPV vaccine has been approved, with approximately 1 billion yuan invested in research and development as of May 2025 [5] - Yuheng Pharmaceutical's subsidiary has signed a market promotion service agreement with Eisai (China) Pharmaceutical for the exclusive promotion of mecobalamin injection, which is used for peripheral neuropathy and vitamin B12 deficiency-related anemia [6]